RxDoctor Payments Data

Muhammad Hizkil, MD

Internal Medicine · Saint Cloud, FLNPI 1578511861

Payments from drug & device makers

$2,222in general payments, 2019–2025

Across 87 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$508
  • Novo Nordisk$381
  • GSK$238
  • Pfizer$225
  • Bayer$211
  • AbbVie$129
  • plus $531 from 9 others

What the payments were for

  • Food & beverage$2,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,222 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$28,416
Medicare patients
62
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide117$149,675
OzempicSemaglutide109$106,144
JardianceEmpagliflozin84$91,343
FarxigaDapagliflozin Propanediol66$80,281
EliquisApixaban85$75,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$48,073
MounjaroTirzepatide29$39,181
JanuviaSitagliptin Phosphate13$22,498
XareltoRivaroxaban12$19,909
EntrestoSacubitril/Valsartan14$13,092
LinzessLinaclotide12$10,400
Celecoxib262$9,976
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$9,032
Atorvastatin Calcium1,024$8,780
SymbicortBudesonide/Formoterol Fumarate25$7,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$49$188,856146 claims
Novo NordiskOzempic$381$106,144109 claims
Boehringer IngelheimJardiance$112$91,34384 claims
AstraZenecaFarxiga, Symbicort$508$87,30891 claims
PfizerEliquis$225$75,61085 claims
GSKTrelegy Ellipta$238$48,07356 claims
MerckJanuvia$80$22,49813 claims
Johnson & JohnsonXarelto$65$19,90912 claims
NovartisEntresto$13$13,09214 claims
AbbVieLinzess$129$10,40012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Saint Cloud

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →